Physician profile
Karsten L Lee
NPI 1851405906
$4,782.49
in general payments reported to CMS, 2019-2025
19 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $174 · 2021: $181 · 2022: $1,063 · 2023: $543 · 2024: $882 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,444 · Entertainment: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.94 |
| Entertainment | $104.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,402.85 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $896.23 | 2022-2025 | Biotrue One Day, Infuse, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $631.58 | 2019-2021 | |
| Amgen INC. | $343.61 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $295.10 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $247.05 | 2023-2025 | Tearcare System, Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $202.41 | 2019-2021 | |
| Alcon Vision LLC | $193.28 | 2022-2025 | Tryptyr, Total30 |
| Sun Pharmaceutical Industries INC. | $164.18 | 2021-2025 | |
| Coopervision INC. | $106.57 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Optos, INC. | $104.35 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $38.01 | 2021-2023 | |
| Abbvie INC. | $36.41 | 2023-2025 | |
| Oyster Point Pharma, INC. | $25.88 | 2022 | |
| Harrow Eye, LLC | $23.48 | 2025 | Vevye |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $22.18 | 2023 | Meibomian Gland Evaluator, Lipiflow System Activator (Disposable) |
| Horizon Therapeutics Plc | $21.63 | 2023 | Tepezza |
| Allergan, INC. | $14.28 | 2022 | |
| Kala Pharmaceuticals, INC. | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karsten Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.